

Company Profile

Industry Sector: Biotech/pharma

Company Overview: Synedgen develops a platform of proprietary polysaccharide derivatives to control microbial populations in biofilms and at tissue interfaces to prevent infection, reduce inflammation and stimulate healing.

Target Market(s): Dermal, ophthalmic, mucosal anti-inflammatory and antibiofilm with wound regenerative capabilities. Primary markets: Oral mucositis treatment, sinusitis treatment, burn and wound infection prophylactic/regenerative therapeutic, ophthalmic drop for enhances healing and reduced scar formation

Key Value Drivers

Technology: Topical Treatment for Radiation Induced Oral Mucositis

Competitive Advantages:

- no currently approved treatments
- both regenerative and anti-infective
- out-patient therapeutic
- excellent price point

Plan & Strategy: Take 1-3 products through Phase 2 clinical trials; partner or sell. Support efforts with veterinary products and international cosmetic oral care products.

Management

Board of Directors: William Wiesmann, MD; Larry Shapiro, MD; Gregory Kenton, MD; Diane Olmstead; Clarke Atwell

Leadership & Advisors: William Wiesmann, CEO; Shenda Baker, President; Dr. Steve Sonis, Brigham Womens Hosp.; Dr. Ed Truelove, U. Wash; Dr. Joel Epstein, Cedar Sinai/City of Hope; Dr. Greg Davis, U. Wash.; Dr. John Sheppard, VA Vision Center; Dr. Brian Gilger, NCSU

5 keywords

Biofilm, anti-inflammatory, anti-infective, tissue regeneration, reduced scar formation

Product Pipeline

Target	In Vitro Efficacy	In Vivo Done (status)	Anticipated Human Trial
Sinusitis (CF Patients)	Complete	Ex vivo sputum/mucus	Q03 12
Oral Mucositis	Complete	Hamsters (ongoing)	Q01 13
Surgical Site Infection	Complete	Porcine (ongoing)	Q01 13
Wound Healing	Complete	Porcine (ongoing)	TBD
Ophthalmic	Complete	Rabbit (ongoing)	TBD